LogicBio Therapeutics, Inc. (LOGC) To Spend Proceeds of Public Offering To Strengthen Its Product Development Plans
LogicBio Therapeutics, Inc. (LOGC) is a biotechnology company dedicated to extend the scope of genetic medicine with pioneering targeted delivery platforms. The company recently closed the underwritten public offering of its common stock. The company offered 8.05 million shares of its common stock to the public at a per share price of $6.00. Included in […]
